Fabian T. Kraus

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancer.

Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancer.

Journal: Frontiers in oncology

Published: February 20, 2026

Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis).

Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis).

Journal: Archives of gynecology and obstetrics

Published: September 11, 2025

Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancer.

Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancer.

Journal: iScience

Published: May 19, 2025

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Journal: Journal of visualized experiments : JoVE

Published: March 11, 2024

Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.

Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.

Journal: International journal of molecular sciences

Published: January 14, 2024

Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential.

Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential.

Journal: STAR protocols

Published: March 31, 2023

Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.

Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.

Journal: Journal of cancer research and clinical oncology

Published: February 09, 2023

PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer.

PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer.

Journal: International journal of molecular sciences

Published: October 16, 2022

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.

Journal: Journal of cancer research and clinical oncology

Published: July 25, 2022

Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer.

Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer.

Journal: Journal of cancer research and clinical oncology

Published: April 18, 2022

The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.

The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.

Journal: Cells

Published: June 30, 2021

AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.

AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.

Journal: Scientific reports

Published: June 14, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026